ۼ : 08-10-13 12:16
Elan immunotherapy
 ۾ :
ȸ : 10,234  
Elan & Wyeth Immunotherapy Clinical Trials (2008 7 ICAD)

Bapineuzumab: Phase II trial (18 months)

The 1st humanized monoclonal antibody
240 AD patients (mild to moderate)
4 doses (0.15, 0.5, 1.0 & 2.0 mg/kg)

ADAS-Cog (AD assessments scale)
NTB (Neuropsychological test battery)
MMSE (mini mental status examination)
CDR-SB (Clinical dementia rating-sum of boxes)

Overall no statistically significant
ApoE4 non-carrier group (40% of whole) showed beneficial effect